Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pathways to Endocrine Therapy Resistance in Breast Cancer
Md. Moquitul Haque, Kartiki V. Desai
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 127

Showing 1-25 of 127 citing articles:

The lingering mysteries of metastatic recurrence in breast cancer
Alessandra I. Riggio, Katherine E. Varley, Alana L. Welm
British Journal of Cancer (2020) Vol. 124, Iss. 1, pp. 13-26
Open Access | Times Cited: 440
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer
Elizabeth Varghese, Samson Mathews Samuel, Alena Líšková, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2252-2252
Open Access | Times Cited: 161
MAZ-mediated tumor progression and immune evasion in hormone receptor-positive breast cancer: Targeting tumor microenvironment and PCLAF+ subtype-specific therapy
Gaofeng Ni, Yuwei Sun, Hongling Jia, et al.
Translational Oncology (2025) Vol. 52, pp. 102280-102280
Closed Access | Times Cited: 4
Multiomic analysis of cytokines in immuno-oncology
Vladimir Jurišić
Expert Review of Proteomics (2020) Vol. 17, Iss. 9, pp. 663-674
Closed Access | Times Cited: 136
Notch Signaling in Breast Cancer: A Role in Drug Resistance
McKenna BeLow, Clodia Osipo
Cells (2020) Vol. 9, Iss. 10, pp. 2204-2204
Open Access | Times Cited: 87
Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
Esmael Besufikad Belachew, Dareskedar Tsehay Sewasew
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 76
<p>ERα, A Key Target for Cancer Therapy: A Review</p>
Yanfang Liu, Hong Ma, Jing Yao
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 2183-2191
Open Access | Times Cited: 74
Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications
Gulab Sher, Nadia Aziz Salman, Abdul Quaiyoom Khan, et al.
Seminars in Cancer Biology (2020) Vol. 83, pp. 152-165
Open Access | Times Cited: 74
Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects
Kah Min Yap, Mahendran Sekar, Yuan Seng Wu, et al.
Saudi Journal of Biological Sciences (2021) Vol. 28, Iss. 12, pp. 6730-6747
Open Access | Times Cited: 60
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer
Jieun Park, Eun Sol Chang, Ji‐Yeon Kim, et al.
Breast Cancer Research (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 10
Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
Ebrahim Rahmani Moghadam, Hui Li Ang, Sholeh Etehad Asnaf, et al.
Biomolecules (2020) Vol. 10, Iss. 10, pp. 1374-1374
Open Access | Times Cited: 57
‘Omics Approaches to Explore the Breast Cancer Landscape
Joseph Parsons, Chiara Francavilla
Frontiers in Cell and Developmental Biology (2020) Vol. 7
Open Access | Times Cited: 52
CCND1 Amplification in Breast Cancer -associations With Proliferation, Histopathological Grade, Molecular Subtype and Prognosis
Marit Valla, Elise Klæstad, Borgny Ytterhus, et al.
Journal of Mammary Gland Biology and Neoplasia (2022) Vol. 27, Iss. 1, pp. 67-77
Open Access | Times Cited: 30
Prognostic and Predictive Value of CCND1/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis
Sarah A. Jeffreys, Therese M. Becker, Sarah Khan, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 28
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
Maysa Abu‐Khalaf, K. Alex Hodge, Christos Hatzis, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 21
Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases
Priyanka Dey Talukdar, Urmi Chatterji
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 21
Cytotoxic effects, carbonic anhydrase isoenzymes, α-glycosidase and acetylcholinesterase inhibitory properties, and molecular docking studies of heteroatom-containing sulfonyl hydrazone derivatives
Hasan Ufuk Çelebioğlu, Yavuz Erden, Fatma Hamurcu, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 15, pp. 5539-5550
Closed Access | Times Cited: 48
Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
John M.S. Bartlett, Dennis C. Sgroi, Kai Treuner, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 9, pp. 1871-1880
Open Access | Times Cited: 27
The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance
Mary Abdelmalak, Rajanbir Singh, Mohammed Anwer, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5388-5388
Open Access | Times Cited: 23
Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer
Oliver Treeck, Silke Haerteis, Olaf Ortmann
Cancers (2023) Vol. 15, Iss. 6, pp. 1632-1632
Open Access | Times Cited: 15
Exploratory drug discovery in breast cancer patients: A multimodal deep learning approach to identify novel drug candidates targeting RTK signaling
Anush Karampuri, Sunitha Kundur, Perugu Shyam
Computers in Biology and Medicine (2024) Vol. 174, pp. 108433-108433
Closed Access | Times Cited: 5
Investigating the potential of mono-chalcone compounds in targeting breast cancer receptors through network pharmacology, molecular docking, molecular dynamics simulation, antiproliferative effects, and gene expressions
Noor Zafirah Ismail, Melati Khairuddean, Mohammad Murwih Alidmat, et al.
3 Biotech (2024) Vol. 14, Iss. 6
Closed Access | Times Cited: 5
The other side of the coin: protein deubiquitination by Ubiquitin-Specific Protease 1 in cancer progression and therapy
Xinlan Hu, Yan Wu, Mengmeng Yao, et al.
Future Medicinal Chemistry (2025) Vol. 17, Iss. 3, pp. 329-345
Closed Access
miRNAs as emerging predictors of tamoxifen resistance in breast cancer
Elmira Aboutalebi Vand Beilankouhi, Reza Safaralizadeh, Babak Nejati, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer
Shivaprasad Gadag, Shristi Sinha, Yogendra Nayak, et al.
Pharmaceutics (2020) Vol. 12, Iss. 6, pp. 524-524
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top